NCT Number: NCT00334997
Endoscopic Surgery or Radiation Therapy in Treating Patients With Stage 0, Stage I, or Stage II Laryngeal Cancer of the Glottis
RATIONALE: Endoscopic surgery is a less invasive type of surgery for laryngeal cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether endoscopic surgery is more effective than radiation therapy in treating laryngeal cancer of the glottis.
PURPOSE: This randomized phase II trial is studying endoscopic surgery to see how well it works compared with radiation therapy in treating patients with stage 0, stage I, or stage II laryngeal cancer of the glottis.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Southmead Hospital, Bristol, England, United Kingdom
About this study
OBJECTIVES:
- Determine the feasibility of conducting a large phase III randomized study in the future, comparing radiotherapy vs endoscopic excision in patients with stage 0-II laryngeal cancer of the glottis.
- Determine patient acceptability of the proposed trial design.
- Compare the effect of using dedicated head and neck research nurses vs general nurses on patient recruitment.
- Refine outcome measures, including voice analysis and quality of life.
OUTLINE: This is a randomized, controlled, multicenter, pilot study. Patients are stratified according to participating center and T stage (Tis or T1 vs T2a). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo endoscopic excision via CO_2 laser or cold steel.
- Arm II: Patients undergo radiotherapy once daily, 5 days a week, for 3-4 weeks. Patients undergo vocal analysis at baseline and at 6 months and 1 and 2 years after randomization.
Quality of life is assessed at baseline, at 1 year, and then annually for 5 years.
After completion of study treatment, patients are followed periodically for up to 5 years.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
DISEASE CHARACTERISTICS:
- Histologically confirmed squamous cell carcinoma of the glottic larynx, including tumors at the anterior commissure
- Stage 0-II (Tis, T1, or T2a)
- No clinical or radiological sign of nodal involvement
- No evidence of distant metastases
- Airway anatomy suitable for endoscopic excision
PATIENT CHARACTERISTICS:
- Fit to receive radical treatment as either radiotherapy or endoscopic excision
- Life expectancy ≥ 2 years
- No other cancer in the past 10 years except basal cell carcinoma of the skin or adequately treated carcinoma in situ of the uterine cervix
- No vasculitic conditions adversely affecting radiotherapy
- No other co-existing medical condition that would limit life expectancy
- Not pregnant
PRIOR CONCURRENT THERAPY:
- No concurrent chemotherapy
- No concurrent palliative treatment
Treatment and study plan
laser surgery
Procedureradiation therapy
RadiationPrimary outcomes
-
Feasibility
-
Patient acceptability
Secondary outcomes
-
Voice analysis
-
Quality of life
-
Economic assessment
Sponsors and collaborators
Lead sponsor
University College London Hospitals
Other
Registry information
Official study title
Early Stage Glottic Cancer: Endoscopic Excision or Radiotherapy [EaStER]
Important dates
- Study start
- 2005
- Study completion
- 2006
- First posted
- Jun 8, 2006
- Registry last updated
- Dec 19, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
NCT03082534
Carcinoma, Carcinoma, Squamous Cell
La Jolla, California, United States
View Trial DetailsPhotodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx
NCT00675233
Carcinoma, Carcinoma, Squamous Cell
Buffalo, New York, United States
View Trial DetailsDocetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
NCT07667400
Adenocarcinoma, Adenoid Cystic Carcinoma
Bethesda, Maryland, United States
View Trial DetailsThermotherapy for Head and Neck Cancer Patients
NCT07690618
Body Temperature Changes, Carcinoma
Rotterdam, South Holland, Netherlands
View Trial Details